Background illustration for clinical trials search

Pancreatic Cancer Clinical Trials

Browse 1,722 pancreatic cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1

Study of AVZO-021 in Patients With Advanced Solid Tumors

for
Advanced Solid Tumor, HR+/HER2- Breast Cancer,
Location: Mineola NY, New York NY, Sarasota FL, Portland OR,
Sponsor: Avenzo Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT05867251

Phase 1, Phase 2, Recruiting

A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors

for
Solid Tumor
Location: Dallas TX
Sponsor: Abbisko Therapeutics Co, Ltd

Sex: All

Age: 18+

Code: NCT05244551

Phase 1, Recruiting

IMPACT: IMplementation of Physical Activity for Children and Adolescents on Treatment

for
Pediatric Cancer, Pediatric Hematology
Location: Edmonton, Calgary
Sponsor: University of Calgary

Sex: All

Age: 5 - 18

Code: NCT04956133

Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

for
Advanced Solid Tumors, Colorectal Cancer
Location: New Brunswick NJ, Toronto, Atlanta GA, Ann Arbor MI,
Sponsor: Vividion Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT06004245

Phase 1, Recruiting

A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer

for
Solid Tumor, Epithelial Ovarian Cancer, Fallopian Tube Cancer,
Location: Boston MA, Providence RI, New York NY, Durham NC,
Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc

Sex: Female

Age: 18+

Code: NCT04516447

Phase 1, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

Study to Evaluate Maximum Tolerated Dose of Oral CB-03-10 With Dose Expansion Phase, in Advanced Solid Tumors

for
Advanced Refractory Solid Tumors,
Location: New Haven CT, Ohio City OH, Michigan Center MI,
Sponsor: Cosmo Technologies Ltd

Sex: All

Age: 18+

Code: NCT03863145

Early Phase 1, Recruiting

Bromelain, Comosain as a New Drug for Treating and Preventing Various Types of Cancer in the Humans

for
Cancer
Location: West Covina CA
Sponsor: Oeyama-Moto Cancer Research Foundation

Sex: All

Age: 18 - 70+

Code: NCT02340845

Phase 2, Recruiting

Statins to Prevent Cancer Associated Blood Clots

for
Venous Thromboembolism, Cancer, Cardiovascular Events
Location: Boston MA, New Haven CT, Miami FL, Rochester MN,
Sponsor: Brigham and Women's Hospital

Sex: All

Age: 18+

Code: NCT07303816

Recruiting

FOCUS for Pediatric Sickle Cell Disease and Cancer

for
Pediatric Cancer, Sickle Cell Disease, Quality of Life,
Location: Atlanta GA
Sponsor: Georgia State University

Sex: All

Age: 12 - 18

Code: NCT04075877

Recruiting

Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer

for
Stage 1 cT1b-T1cN0M0, Triple Negative Breast Cancer
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT06318897

Phase 2, Recruiting

QTX3034 in Patients With KRAS G12D Mutation

for
Solid Tumors
Location: New Haven CT, The Bronx NY, New York NY, Fairfax VA,
Sponsor: Quanta Therapeutics

Sex: All

Age: 18+

Code: NCT06227377

Phase 1, Recruiting

A Phase I Open-Label, Single-Arm, Dose-Escalation Clinical and Pharmacology Study of CCI-001 as Monotherapy and in Combination With Standard Chemotherapy in Patients With Recurrent and/or Metastatic Solid Tumours

for
Cancer: Recurrent and/or Metastatic Solid Tumours
Location: Edmonton
Sponsor: PharmaMatrix Holdings Ltd

Sex: All

Age: 18+

Code: NCT04823897

Phase 1, Recruiting

Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies

for
Cancer
Location: Lexington KY
Sponsor: Rachel Miller

Sex: All

Age: 18+

Code: NCT03089554

Phase 2, Recruiting

Virtual Group Resilient Living Program For Patients Living With Advanced Cancer

for
Advanced Cancer
Location: Rochester MN
Sponsor: Mayo Clinic

Sex: All

Age: 18+

Code: NCT07659158

Recruiting

A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications.

for
Cancer, Immunotherapy, PD-1, PD-L1, Immune Checkpoint Therapy
Location: Norwich CT, Rock Hill SC, Dublin GA
Sponsor: Oxford Biodynamics Inc.

Sex: All

Age: 18+

Code: NCT06635954

Recruiting

A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation

for
Advanced Solid Tumors
Location: New Haven CT, Fairfax VA, Houston TX
Sponsor: Nutshell Therapeutics (Shanghai) Co., LTD.

Sex: All

Age: 18+

Code: NCT07060989

Phase 1, Phase 2, Recruiting

Investigating the Feasibility and Acceptability of an Innovative Interdisciplinary Supportive Care Program: Couples Coping Together Against Cancer

for
Anatomic Stage IV Breast Cancer AJCC v8, Glioblastoma,
Location: Duarte CA
Sponsor: City of Hope Medical Center

Sex: All

Age: 18+

Code: NCT07664579

Recruiting

Evaluation of Portal Vein Stenting in Patients With Portal Vein Stenosis and Gastrointestinal Cancers

for
Malignant Digestive System Neoplasm
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT04629677

Recruiting

Norris ORIEN Total Cancer Care

for
Cancer Risk, Malignant Neoplasm
Location: Los Angeles CA
Sponsor: University of Southern California

Sex: All

Age: 18+

Code: NCT02970045

Recruiting

A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment

for
Primary Extra-cranial Solid Tumor,
Location: Boston MA, New York NY, Atlanta GA, Cincinnati OH,
Sponsor: Memorial Sloan Kettering Cancer Center

Sex: All

Age: 1 - 21

Code: NCT04928677

Phase 1, Recruiting

What is pancreatic cancer?

The pancreas sits deep behind the stomach and makes both digestive enzymes and hormones like insulin. About 92 percent of pancreatic cancers start in the enzyme making cells, and this page is mostly about those. The other 8 percent are neuroendocrine tumors, which grow more slowly, have their own trials, and a five year survival of 72 percent against 8 percent. The pancreas gives no early warning. Jaundice, back pain, weight loss and new diabetes usually appear only after the cancer has grown or spread, and fewer than 20 percent of people can have surgery at diagnosis.

Smoking roughly doubles the risk, and type 2 diabetes, extra weight, chronic pancreatitis and family history raise it. About 10 percent of cases come from inherited mutations, so guidelines now recommend genetic testing for everyone diagnosed. That can change treatment and flag relatives who should be watched. The hope comes from biology. More than 90 percent of pancreatic cancers carry a KRAS mutation. That target was called undruggable for decades. Now several RAS inhibitors are in trials, with the first Phase 3 studies recruiting. Pancreatic cancer shares risk factors with type 2 diabetes and inherited genes with breast and ovarian cancer.

Article preview image

Our guide to new treatments for pancreatic cancer covers what has been approved and what is being tested.

Research Paving The Way To A New Treatment For Pancreatic Cancer

Types of pancreatic cancer clinical trials

Who can participate in pancreatic cancer clinical trials?

What causes pancreatic cancer?

The stages of pancreatic cancer, and why they matter for trials

How to enroll in a pancreatic cancer clinical trial